Long R. Jiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Long R. Jiao has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Adam Enver Frampton
Faculty of Health and Medical Sciences, University of Surrey
4 shared publications - Nagy Habib
Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK; MiNA Therapeutics Ltd, W12 0BZ London, UK
3 shared publications - Tamara M. H. Gall
HPB Surgical Unit, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, UK
3 shared publications - Duncan Spalding
Department of Surgery and Cancer, School of Medicine, Imperial College London, London, United Kingdom
2 shared publications - Jonathan Krell
Institute of Reproductive and Developmental Biology
2 shared publications - Justin Stebbing
Department of Surgery and Cancer, Imperial College London, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 25 October 2022
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 7, 42
Hepatic epithelioid hemangioendothelioma (HEHE)—rare vascular malignancy mimicking cholangiocarcinoma: a case report
Hepatic epithelioid hemangioendothelioma (HEHE)—rare vascular malignancy mimicking cholangiocarcinoma: a case report Michal Kawka, Sau Mak, Shengyang Qiu, Tamara M. H. Gall, Long R. Jiao
- 25 October 2022
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 7, 42
Open AccessHepatic epithelioid hemangioendothelioma (HEHE)—rare vascular malignancy mimicking cholangiocarcinoma: a case report
Hepatic epithelioid hemangioendothelioma (HEHE)—rare vascular malignancy mimicking cholangiocarcinoma: a case report Michal Kawka, Sau Mak, Shengyang Qiu, Tamara M. H. Gall, Long R. Jiao
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 35 (1) , e1683
HOW TO PERFORM LAPAROSCOPIC DISTAL PANCREATECTOMY USING THE CLOCKWISE TECHNIQUE
- BACKGROUND: Laparoscopic pancreatectomy is currently a widely used approach for benign and malignant lesions of the pancreas. AIMS: This study aimed to describe how to perform a laparoscopic distal pancreatectomy using The Clockwise Technique. METHODS: An 18-year-old female patient presented with a well-defined tumor in the pancreatic body with 4 cm in diameter that suggested a diagnosis of solid pseudopapillary tumor (Frantz’s tumor). The patient was recommended for laparoscopic distal pancreatectomy by using The Clockwise Technique. RESULTS: The clockwise, caudal-to-cephalic approach appears to have other significant technical advantages that facilitate the performance of the procedure. CONCLUSIONS: A laparoscopic distal pancreatectomy performed using The Clockwise Technique provides satisfactory outcomes.
- 1 January 2022
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 35 (1) , e1683
Open AccessHOW TO PERFORM LAPAROSCOPIC DISTAL PANCREATECTOMY USING THE CLOCKWISE TECHNIQUE
- BACKGROUND: Laparoscopic pancreatectomy is currently a widely used approach for benign and malignant lesions of the pancreas. AIMS: This study aimed to describe how to perform a laparoscopic distal pancreatectomy using The Clockwise Technique. METHODS: An 18-year-old female patient presented with a well-defined tumor in the pancreatic body with 4 cm in diameter that suggested a diagnosis of solid pseudopapillary tumor (Frantz’s tumor). The patient was recommended for laparoscopic distal pancreatectomy by using The Clockwise Technique. RESULTS: The clockwise, caudal-to-cephalic approach appears to have other significant technical advantages that facilitate the performance of the procedure. CONCLUSIONS: A laparoscopic distal pancreatectomy performed using The Clockwise Technique provides satisfactory outcomes.
- Open Access
- 18 August 2021
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 15 (10) , 1159-1167
Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma
Recurrence is the driving factor for reduced long-term survival in patients following resected hepatocellular carcinoma (HCC). Extensive research efforts have been conducted to understand the molec...
- 18 August 2021
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 15 (10) , 1159-1167
Open AccessClinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma
Recurrence is the driving factor for reduced long-term survival in patients following resected hepatocellular carcinoma (HCC). Extensive research efforts have been conducted to understand the molec...
- Open Access
- 3 August 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (11) , 2897-2911
Immunological combination treatment holds the key to improving survival in pancreatic cancer
Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing results proposing other means by which the tumour microenvironment serves to decrease the immune response. Additionally, the emergence of various subtypes of pancreatic cancer has emerged as a factor for treatment responses with immunogenic subtypes carrying a better prognosis. Herein we discuss the reasons for the poor response to checkpoint inhibitors and outline a rationale why combination treatments are likely to be most effective. We review the therapies which could provide optimal synergistic effects to immunotherapy including chemotherapy, agents targeting the stroma, co-stimulatory molecules, vaccinations and methods of immunogenic tumour priming including radiofrequency ablation. Finally, we discuss reasons why peri-operative and in particular neoadjuvant combination treatments are likely to be most effective and should be considered for early clinical trials.
- 3 August 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (11) , 2897-2911
Open AccessImmunological combination treatment holds the key to improving survival in pancreatic cancer
Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing results proposing other means by which the tumour microenvironment serves to decrease the immune response. Additionally, the emergence of various subtypes of pancreatic cancer has emerged as a factor for treatment responses with immunogenic subtypes carrying a better prognosis. Herein we discuss the reasons for the poor response to checkpoint inhibitors and outline a rationale why combination treatments are likely to be most effective. We review the therapies which could provide optimal synergistic effects to immunotherapy including chemotherapy, agents targeting the stroma, co-stimulatory molecules, vaccinations and methods of immunogenic tumour priming including radiofrequency ablation. Finally, we discuss reasons why peri-operative and in particular neoadjuvant combination treatments are likely to be most effective and should be considered for early clinical trials.
- 10 June 2019
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 19 (7) , 553-558
Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?. Expert Review of Molecular Diagnostics. Accepted 20 May 2019.
- 10 June 2019
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 19 (7) , 553-558
Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?. Expert Review of Molecular Diagnostics. Accepted 20 May 2019.
- 16 May 2014
- Published by Wiley in Colorectal Disease
- Vol. 16 (6) , O197-O205
Neoadjuvant chemotherapy and primary‐first approach for rectal cancer with synchronous liver metastases
Aim: Up to a quarter of patients with rectal cancer have synchronous liver metastases at the time of diagnosis. This is a predictor of poor outcome. There are no standardized guidelines for treatment. We reviewed the outcomes of our patients with synchronous rectal liver metastases treated with a curative intent by neoadjuvant chemotherapy with or without chemoradiotherapy followed by resection of the primary tumour and then liver metastases.Method: Between 2004 and 2012, patients who presented with rectal cancer and synchronous liver metastasis were treated with curative intent with peri‐operative systemic chemotherapy as the first line of treatment. Responders to chemotherapy underwent resection of the primary tumour with or without preoperative chemoradiotherapy followed by hepatic resection.Results: Fifty‐three rectal cancer patients with 152 synchronous liver lesions were identified. After a median follow‐up of 29.6 months, the median survival was 41.4 months. Overall survival was 59.0% at 3 years and 39.0% at 5 years.Conclusion: Rectal resection before hepatic resection combined with neoadjuvant chemotherapy is associated with promising clinical outcome. It allows downstaging of liver lesions and removal of the primary tumour before the progression of further micrometastases. Furthermore, patients who do not respond to chemotherapy can be identified and may avoid major surgical intervention.
- 16 May 2014
- Published by Wiley in Colorectal Disease
- Vol. 16 (6) , O197-O205
Neoadjuvant chemotherapy and primary‐first approach for rectal cancer with synchronous liver metastases
Aim: Up to a quarter of patients with rectal cancer have synchronous liver metastases at the time of diagnosis. This is a predictor of poor outcome. There are no standardized guidelines for treatment. We reviewed the outcomes of our patients with synchronous rectal liver metastases treated with a curative intent by neoadjuvant chemotherapy with or without chemoradiotherapy followed by resection of the primary tumour and then liver metastases.Method: Between 2004 and 2012, patients who presented with rectal cancer and synchronous liver metastasis were treated with curative intent with peri‐operative systemic chemotherapy as the first line of treatment. Responders to chemotherapy underwent resection of the primary tumour with or without preoperative chemoradiotherapy followed by hepatic resection.Results: Fifty‐three rectal cancer patients with 152 synchronous liver lesions were identified. After a median follow‐up of 29.6 months, the median survival was 41.4 months. Overall survival was 59.0% at 3 years and 39.0% at 5 years.Conclusion: Rectal resection before hepatic resection combined with neoadjuvant chemotherapy is associated with promising clinical outcome. It allows downstaging of liver lesions and removal of the primary tumour before the progression of further micrometastases. Furthermore, patients who do not respond to chemotherapy can be identified and may avoid major surgical intervention.
- Open Access
- 1 May 2014
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 149 (5) , 482-485
Reduced Dissemination of Circulating Tumor Cells With No-Touch Isolation Surgical Technique in Patients With Pancreatic Cancer
Circulating tumor cells (CTCs) disseminate from the primary tumor and travel through the bloodstream and lymphatic system. The detection of and/or increase in the number of CTCs during a patient’s clinical course may be a harbinger of forthcoming overt metastasis. We aimed to examine the impact of 2 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT) PD, on tumor behavior and outcome in patients with pancreatic cancer by using CTCs as biomarkers. In this pilot study, patients were randomized to either ST-PD (n = 6) or NT-PD (n = 6). Intraoperatively, blood samples were taken from the portal vein for measurement of CTCs before and immediately after removal of the tumor. An increase in CTCs was seen in 5 of 6 patients (83%) with ST-PD but no patients with NT-PD (P = .003). In the ST-PD and NT-PD groups, median overall survival was 13.0 and 16.7 months, respectively (P = .33); there was no difference in disease-free survival (P = .42). The use of NT-PD significantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compared with ST-PD, although more extensive studies are required.
- 1 May 2014
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 149 (5) , 482-485
Open AccessReduced Dissemination of Circulating Tumor Cells With No-Touch Isolation Surgical Technique in Patients With Pancreatic Cancer
Circulating tumor cells (CTCs) disseminate from the primary tumor and travel through the bloodstream and lymphatic system. The detection of and/or increase in the number of CTCs during a patient’s clinical course may be a harbinger of forthcoming overt metastasis. We aimed to examine the impact of 2 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT) PD, on tumor behavior and outcome in patients with pancreatic cancer by using CTCs as biomarkers. In this pilot study, patients were randomized to either ST-PD (n = 6) or NT-PD (n = 6). Intraoperatively, blood samples were taken from the portal vein for measurement of CTCs before and immediately after removal of the tumor. An increase in CTCs was seen in 5 of 6 patients (83%) with ST-PD but no patients with NT-PD (P = .003). In the ST-PD and NT-PD groups, median overall survival was 13.0 and 16.7 months, respectively (P = .33); there was no difference in disease-free survival (P = .42). The use of NT-PD significantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compared with ST-PD, although more extensive studies are required.
- 9 January 2013
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 13 (1) , 31-34
Towards a clinical use of miRNAs in pancreatic cancer biopsies
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, despite advances in imaging, surgery and a greater understanding of its molecular biology. Patient outcomes remain poor due to an inability to detect disease early and resistance to anticancer treatments. miRNAs are promised to become ideal cancer biomarkers, as they are tumor and tissue specific and also incredibly stable molecules. So far, large profiling studies of the PDAC miRNome have identified the 'usual suspects' known to be deregulated in solid tumors, such as oncomiR-21, as well as others that could be more robust for differentiating malignant from benign pancreatic disease. However, many of these are yet to be validated clinically. The paper under evaluation provides further evidence for the use of miRNAs as diagnostic biomarkers for PDAC. We have reviewed the use of miRNAs as diagnostic analytes for detecting PDAC in biopsies.
- 9 January 2013
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 13 (1) , 31-34
Towards a clinical use of miRNAs in pancreatic cancer biopsies
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, despite advances in imaging, surgery and a greater understanding of its molecular biology. Patient outcomes remain poor due to an inability to detect disease early and resistance to anticancer treatments. miRNAs are promised to become ideal cancer biomarkers, as they are tumor and tissue specific and also incredibly stable molecules. So far, large profiling studies of the PDAC miRNome have identified the 'usual suspects' known to be deregulated in solid tumors, such as oncomiR-21, as well as others that could be more robust for differentiating malignant from benign pancreatic disease. However, many of these are yet to be validated clinically. The paper under evaluation provides further evidence for the use of miRNAs as diagnostic biomarkers for PDAC. We have reviewed the use of miRNAs as diagnostic analytes for detecting PDAC in biopsies.
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB377-AB378
Mo1291 Radiofrequency Ablation for Biliary Metal Stent Occlusion: Evolution of a Novel Endoscopic Technique and Proof of Concept
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB377-AB378
Mo1291 Radiofrequency Ablation for Biliary Metal Stent Occlusion: Evolution of a Novel Endoscopic Technique and Proof of Concept